PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Relation between cost of drug treatment and body mass index in people with type 2 diabetes in Latin America.

Abstract Despite the frequent association of obesity with type 2 diabetes (T2D), the effect of the former on the cost of drug treatment of the latest has not been specifically addressed. We studied the association of overweight/obesity on the cost of drug treatment of hyperglycemia, hypertension and dyslipidemia in a population with T2D.
PMID
Related Publications

Relationships between obesity, glycemic control, and cardiovascular risk factors: a pooled analysis of cross-sectional data from Spanish patients with type 2 diabetes in the preinsulin stage.

The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.

Bariatric surgery: an evidence-based analysis.

The effectiveness of web-based programs on the reduction of childhood obesity in school-aged children: A systematic review.

Evaluation of the quality of care for diabetic patients in Latin America.

Authors

Mayor MeshTerms
Keywords
Journal Title plos one
Publication Year Start




PMID- 29261739
OWN - NLM
STAT- In-Process
LR  - 20171220
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 12
DP  - 2017
TI  - Relation between cost of drug treatment and body mass index in people with type 2
      diabetes in Latin America.
PG  - e0189755
LID - 10.1371/journal.pone.0189755 [doi]
AB  - AIMS: Despite the frequent association of obesity with type 2 diabetes (T2D), the
      effect of the former on the cost of drug treatment of the latest has not been
      specifically addressed. We studied the association of overweight/obesity on the
      cost of drug treatment of hyperglycemia, hypertension and dyslipidemia in a
      population with T2D. METHODS: This observational study utilized data from the
      QUALIDIAB database on 3,099 T2D patients seen in Diabetes Centers in Argentina,
      Chile, Colombia, Peru, and Venezuela. Data were grouped according to body mass
      index (BMI) as Normal (18.5</=BMI<25), Overweight (25</=BMI<30), and Obese
      (BMI>/=30). Thereafter, we assessed clinical and metabolic data and cost of drug 
      treatment in each category. Statistical analyses included group comparisons for
      continuous variables (parametric or non-parametric tests), Chi-square tests for
      differences between proportions, and multivariable regression analysis to assess 
      the association between BMI and monthly cost of drug treatment. RESULTS: Although
      all groups showed comparable degree of glycometabolic control (FBG, HbA1c), we
      found significant differences in other metabolic control indicators. Total cost
      of drug treatment of hyperglycemia and associated cardiovascular risk factors
      (CVRF) increased significantly (p<0.001) with increment of BMI. Hyperglycemia
      treatment cost showed a significant increase concordant with BMI whereas
      hypertension and dyslipidemia did not. Despite different values and percentages
      of increase, this growing cost profile was reproduced in every participating
      country. BMI significantly and independently affected hyperglycemia treatment
      cost. CONCLUSIONS: Our study shows for the first time that BMI significantly
      increases total expenditure on drugs for T2D and its associated CVRF treatment in
      Latin America.
FAU - Elgart, Jorge Federico
AU  - Elgart JF
AUID- ORCID: http://orcid.org/0000-0002-6101-1219
AD  - CENEXA. Center of Experimental and Applied Endocrinology (UNLP-CONICET La Plata),
      School of Medicine, National University of La Plata, La Plata, Argentina.
FAU - Prestes, Mariana
AU  - Prestes M
AD  - CENEXA. Center of Experimental and Applied Endocrinology (UNLP-CONICET La Plata),
      School of Medicine, National University of La Plata, La Plata, Argentina.
FAU - Gonzalez, Lorena
AU  - Gonzalez L
AD  - CENEXA. Center of Experimental and Applied Endocrinology (UNLP-CONICET La Plata),
      School of Medicine, National University of La Plata, La Plata, Argentina.
AD  - School of Health Economics and Management of Healthcare Organizations, Faculty of
      Economic Sciences, National University of La Plata, La Plata, Argentina.
FAU - Rucci, Enzo
AU  - Rucci E
AD  - CENEXA. Center of Experimental and Applied Endocrinology (UNLP-CONICET La Plata),
      School of Medicine, National University of La Plata, La Plata, Argentina.
AD  - III-LIDI, Faculty of Informatics, National University of La Plata, La Plata,
      Argentina.
FAU - Gagliardino, Juan Jose
AU  - Gagliardino JJ
AD  - CENEXA. Center of Experimental and Applied Endocrinology (UNLP-CONICET La Plata),
      School of Medicine, National University of La Plata, La Plata, Argentina.
CN  - QUALIDIAB Net study group
LA  - eng
PT  - Journal Article
DEP - 20171220
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
EDAT- 2017/12/21 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/12/21 06:00
PHST- 2017/07/07 00:00 [received]
PHST- 2017/12/03 00:00 [accepted]
PHST- 2017/12/21 06:00 [entrez]
PHST- 2017/12/21 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
AID - 10.1371/journal.pone.0189755 [doi]
AID - PONE-D-17-25139 [pii]
PST - epublish
SO  - PLoS One. 2017 Dec 20;12(12):e0189755. doi: 10.1371/journal.pone.0189755.
      eCollection 2017.